@Article{Krenska2009,
journal="Contemporary Oncology/Współczesna Onkologia",
issn="1428-2526",
volume="13",
number="2",
year="2009",
title="Successful therapy in post-transplant lymphoproliferative  disorder after allogeneic haematopoietic stem cell  transplantation in resistant Hodgkin\’s disease",
abstract="It has been shown recently that allogeneic haematopoietic stem cell transplantation (HSCT) can be considered  as a clinical option in the treatment of refractory and relapsed Hodgkin\’s  disease. However, potent T-cell immunosuppression predisposes to the development of post-transplant lymphoproliferative disorder (PTLD) in patients after HSCT.  Other well-know risk factors for development of post transplant lymphoproliferative disorder (PTLD) include unrelated or mismatched SCT, T-cell depletion, use of ATG or OKT3, and also HLA mismatch/T-cell depletion, EBV serology mismatch between donor and recipient and splenectomy. The higher the number of risk factors, the higher the frequency of EBV reactivation. We present a case of a patient with refractory Hodgkin\’s disease, who relapsed after autologous HSCT, and subsequently was referred for allogeneic HSCT. At day +90 after transplantation, clinical symptoms of EBV-PTLD developed, and were confirmed by PCR  (EBV-DNA-emia), biopsy and positron emission tomography (CT-PET). The patient was treated with 8 cycles of rituximab and reduction of immunosuppression (RI). Monitoring of the treatment was performed by PCR detection of EBV-DNA and CT-PET scan. Due to the absence of graft-  versus  -host disease (GVHD) symptoms, donor-lymphocyte infusion (DLI) was done, followed by development of GVHD symptoms. One year after allo-HSCT, the patient remains in complete remission, confirmed by negative CT-PET scan and EBV-DNA-emia. In conclusion, allo-HSCT, supported by DLI, might be an effective therapy in refractory/relapsed Hodgkin\’s disease. Based on own experience recent criteria from the literature, we consider rituximab along with reduction of immunotherapy as a first-line therapy in PTLD",
author="Krenska, Anna
and Styczyński, Jan
and Dębski, Robert
and Pogorzała, Monika
and Małkowski, Bogdan
and Wysocki, Mariusz",
pages="85--89",
url="https://www.termedia.pl/Successful-therapy-in-post-transplant-lymphoproliferative-disorder-after-allogeneic-haematopoietic-stem-cell-transplantation-in-resistant-Hodgkin-8217-s-disease,3,12393,1,1.html"
}